Aliases & Classifications for Prostatitis

MalaCards integrated aliases for Prostatitis:

Name: Prostatitis 12 73 54 44 15 17 70

Classifications:



External Ids:

Disease Ontology 12 DOID:14654
ICD9CM 34 601.9
MeSH 44 D011472
NCIt 50 C26866
SNOMED-CT 67 155907007
ICD10 32 N41.9
UMLS 70 C0033581

Summaries for Prostatitis

MalaCards based summary : Prostatitis is related to prostatic hypertrophy and prostatic hyperplasia, benign, and has symptoms including prostatism An important gene associated with Prostatitis is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Povidone and Finasteride have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and lymph node, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 73 Prostatitis is inflammation of the prostate gland. Prostatitis is classified into acute, chronic,... more...

Related Diseases for Prostatitis

Diseases related to Prostatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 797)
# Related Disease Score Top Affiliating Genes
1 prostatic hypertrophy 31.6 KLK3 ADRA1A ACP3
2 prostatic hyperplasia, benign 31.3 PDE5A PCA3 KLK3 ADRA1A ACP3
3 urethritis 31.2 TNF KLK3 IL6 IL1B IL10 CXCL8
4 acute cystitis 31.1 TNF KLK3 IL6 IL1B IL10 CXCL8
5 pyuria 31.0 KLK3 IL6 CXCL8
6 pyelonephritis 31.0 TNF IL6 IL1B IL10 CXCL8
7 chlamydia 31.0 TNF IL6 IL4 IL1B IL17A IL10
8 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.9 IL17A IL10 FOXP3
9 acute pyelonephritis 30.8 IL6 IL10 CXCL8
10 cystitis 30.7 TNF PTGS2 IL6 IL4 IL2 IL17A
11 spinal cord injury 30.7 TNF IL6 CXCL8
12 pertussis 30.7 TNF IL6 IL1B IL10 CXCL8
13 diphtheria 30.6 TNF IL4 IL2 IL1B
14 autoimmune pancreatitis 30.6 TNF IL10 FOXP3
15 bladder neck obstruction 30.5 PDE5A KLK3
16 orchitis 30.5 TNF IL6 IL2 IL1B IL10 FOXP3
17 tetanus 30.5 TNF IL6 IL4 IL2 IL1B IL10
18 irritable bowel syndrome 30.5 TNF IL6 IL4 IL1B IL10 CXCL8
19 melioidosis 30.4 TNF IL6 IL10
20 fibromyalgia 30.4 TNF IL6 IL1B IL10 CXCL8
21 cryptococcosis 30.4 TNF IL4 IL17A IL10
22 meningoencephalitis 30.3 TNF IL6 IL10
23 haemophilus influenzae 30.3 TNF CXCL8
24 trichomoniasis 30.3 TNF IL6 IL2 IL1B IL10 CXCL8
25 bacterial infectious disease 30.3 TNF IL6 IL1B IL17A IL10 CXCL8
26 pustulosis of palm and sole 30.3 TNF IL17A CXCL8
27 cholangitis 30.3 TNF IL6 IL2 IL10 CXCL8
28 paine syndrome 30.3 TNF IL6 IL1B
29 iridocyclitis 30.3 TNF IL6 IL1B IL17A IL10
30 spondylitis 30.3 TNF IL6 IL1B IL17A IL10
31 urethral syndrome 30.3 TNF PCA3 KLK3 IL6 IL1B CXCL8
32 helicobacter pylori infection 30.2 TNF IL1B IL10 CXCL8
33 endophthalmitis 30.2 TNF IL6 IL1B CXCL8
34 pyelitis 30.2 TNF IL6 IL1B CXCL8
35 spondyloarthropathy 1 30.2 TNF IL6 IL17A
36 mental depression 30.2 TNF IL6 IL1B
37 infective endocarditis 30.2 TNF IL6 IL17A
38 osteomyelitis 30.2 TNF IL6 IL4 IL1B IL10 CXCL8
39 syphilis 30.2 TNF IL6 IL17A FOXP3
40 sclerosing cholangitis 30.1 TNF IL6 IL2 IL10 CXCL8
41 tuberculous epididymitis 30.1 TNF KLK3
42 vaginitis 30.1 TNF IL6 IL1B IL10 CXCL8
43 periodontitis, chronic 30.1 IL6 IL1B
44 exanthem 30.1 TNF IL6 IL2 IL1B IL10 CXCL8
45 neutrophilic dermatosis, acute febrile 30.1 TNF IL1B CXCL8
46 tendinitis 30.1 TNF IL6 IL1B
47 toxic shock syndrome 30.1 TNF IL6 IL4 IL2 IL1B IL10
48 herpes zoster 30.1 TNF IL2 IL10
49 endocarditis 30.1 TNF IL6 IL17A IL10 CXCL8
50 chronic granulomatous disease 30.0 TNF IL1B IL17A CXCL8

Comorbidity relations with Prostatitis via Phenotypic Disease Network (PDN):


Acute Cystitis Bladder Neck Obstruction
Epididymo-Orchitis Prostate Calculus
Prostate Cancer Prostatic Hypertrophy
Urethral Stricture Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Prostatitis:



Diseases related to Prostatitis

Symptoms & Phenotypes for Prostatitis

UMLS symptoms related to Prostatitis:


prostatism

GenomeRNAi Phenotypes related to Prostatitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 ADRA1A CXCL8 IL10 IL17A IL1B TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 ADRA1A CXCL8 IL10 IL17A IL1B IL2

MGI Mouse Phenotypes related to Prostatitis:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.27 ADRA1A FOXP3 IL10 IL1B IL2 IL6
2 endocrine/exocrine gland MP:0005379 10.23 ACP3 FOXP3 IL10 IL17A IL2 IL4
3 integument MP:0010771 10.21 ACP3 FOXP3 IL10 IL17A IL1B IL4
4 digestive/alimentary MP:0005381 10.18 FOXP3 IL10 IL17A IL2 IL4 IL6
5 liver/biliary system MP:0005370 10.01 FOXP3 IL10 IL2 IL4 IL6 PROS1
6 muscle MP:0005369 9.97 ADRA1A IL10 IL6 KLK3 PROS1 PTGS2
7 neoplasm MP:0002006 9.97 ACP3 IL10 IL1B IL2 IL6 MSMB
8 no phenotypic analysis MP:0003012 9.91 FOXP3 IL10 IL17A IL2 IL4 NKX3-1
9 reproductive system MP:0005389 9.9 ACP3 FOXP3 IL10 IL2 IL4 IL6
10 respiratory system MP:0005388 9.56 FOXP3 IL10 IL17A IL2 IL4 IL6
11 skeleton MP:0005390 9.32 IL10 IL17A IL1B IL4 IL6 MSMB

Drugs & Therapeutics for Prostatitis

Drugs for Prostatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 839)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Povidone Approved Phase 4 9003-39-8 131751496
2
Finasteride Approved Phase 4 98319-26-7 57363
3
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
4
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
5
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
6
Flutamide Approved, Investigational Phase 4 13311-84-7 3397
7
Amikacin Approved, Investigational, Vet_approved Phase 4 37517-28-5 37768
8
Cycloserine Approved Phase 4 68-41-7 401 6234
9
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
10
Saw palmetto Approved, Experimental, Investigational Phase 4
11
Silodosin Approved Phase 4 160970-54-7
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
13
Prilocaine Approved Phase 4 721-50-6 4906
14
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
15
tannic acid Approved Phase 4 1401-55-4
16
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
17
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
18
Dihydrotachysterol Approved Phase 4 67-96-9 5311071 5281010
19
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
20
Imipenem Approved Phase 4 64221-86-9, 74431-23-5 104838
21
Aztreonam Approved Phase 4 78110-38-0 5362041 5742832
22
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
23
Nitric Oxide Approved Phase 4 10102-43-9 145068
24
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
25
Remifentanil Approved Phase 4 132875-61-7 60815
26
Etidronic acid Approved Phase 4 7414-83-7, 2809-21-4 3305
27
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
28
Ondansetron Approved Phase 4 99614-02-5 4595
29
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
30
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
31
Mivacurium Approved Phase 4 106791-40-6, 133814-19-4 5281042
32
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
33
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
34
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
35
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
36
Desflurane Approved Phase 4 57041-67-5 42113
37
Fesoterodine Approved Phase 4 286930-03-8, 286930-02-7 6918558
38
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
39
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
40
Acetaminophen Approved Phase 4 103-90-2 1983
41
Zoledronic Acid Approved Phase 4 118072-93-8 68740
42
Denosumab Approved Phase 4 615258-40-7
43
Ibuprofen Approved Phase 4 15687-27-1 3672
44
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
45
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
46
Sulfamethoxazole Approved Phase 4 723-46-6 5329
47
Fosfomycin Approved Phase 4 23155-02-4 446987
48
Pamidronate Approved Phase 4 40391-99-9 4674
49
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
50
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613

Interventional clinical trials:

(show top 50) (show all 5260)
# Name Status NCT ID Phase Drugs
1 Prostatic Artery Embolization Versus 532 nm Green Light Laser Photoselective Vaporization of the Prostate for Treating Catheter-Dependent Patients With Benign Prostatic Hyperplasia: A Randomized Controlled Clinical Study Unknown status NCT02006303 Phase 4
2 Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH) Unknown status NCT02021032 Phase 4
3 Ejaculatory Sparing vs. Non-ejaculatory Sparing GreenLightTM Laser Photoselective Vaporization of the Prostate (PVP): A Randomized Double Blind Sexual and Urodynamic Assessment Unknown status NCT02749604 Phase 4
4 Prospective Non-randomized Trial Comparing Holmium Laser Enucleation of the Prostate Versus Greenlight Laser Photoselective Vaporization of the Prostate in Treating Benign Prostate Hyperplasia in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
5 Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)for the Treatment of Clinically Significant Benign Prostate Hyperplasia (BPH) Unknown status NCT00826527 Phase 4 Solifenacin PO
6 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Unknown status NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
7 Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression Unknown status NCT02443844 Phase 4 Tamsulosin
8 Ofloxacin vs. Gentamicin as Prophylaxis Prior Transrectal Biopsy of Prostate Unknown status NCT00480376 Phase 4 ofloxacin;gentamicin
9 A Prospective Randomized Trial of Povidone-iodine Suppository Before Transrectal Ultrasound Guided Prostate Biopsy Unknown status NCT02245334 Phase 4 Povidone-Iodine
10 A Randomised Controlled Trial Comparing Combined Intravenous Propofol and Fentanyl Versus Intravenous Propofol Alone for Sedation in Patients Undergoing Transrectal Ultrasound-guided (TRUS) Prostate Biopsy Unknown status NCT02733705 Phase 4 Fentanyl;propofol
11 METformin And Longevity (METAL): A Window of Opportunity Study Investigating Biological Effects of Metformin in Localised Prostate Cancer Unknown status NCT02511665 Phase 4 Metformin;Placebo
12 Efficiency Study of Aspirin to Prevent the Occurrence of Prostate Cancer Unknown status NCT02757365 Phase 4 aspirin;Levofloxacin
13 Intermittent Vs Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer Unknown status NCT00293670 Phase 4 Goserelin (Zoladex)
14 Kinetics of the Finasteride Prostate Induced Apoptosis Unknown status NCT00130767 Phase 4 finasteride
15 MRI With a Lymph Node Specific Contrast Agent: an Alternative for CT-Scanning and Lymph Node Dissection in Patients With Prostate Cancer? Unknown status NCT00185029 Phase 4
16 To Investigate Post-procedure Hemorrhage and Cardiovascular Events in Taiwanese Patients Who Continue or Discontinue Low-Dose Aspirin Before Transrectal Prostate Biopsy: a Prospective Randomized Trial Unknown status NCT02744937 Phase 4 Aspirin
17 Clinical Pilot Trial on the Influence of a Saw Palmetto Berry Preparation on Sexual Functions in Patients With Benign Prostatic Hyperplasia Unknown status NCT01021267 Phase 4 Saw palmetto berry extract
18 A Pilot Phase IV Study to Evaluate Variation in Bone Mineral Density, Lean and Fat Body Mass Index Measured by Dual-energy X-ray Absorptiometry in Patients With Prostate Cancer Without Bone Metastasis Treated With Degarelix Unknown status NCT03202381 Phase 4 Degarelix
19 Comparison of Health Related Quality of Life and Other Clinical Parameters Between ThinSeed™ and OncoSeed™ for Permanent Low Dose Rate Implantation in Localized Prostate Cancer Unknown status NCT01379742 Phase 4
20 A Randomized, Double-blind, Placebo-controlled, Investigator Initiated Clinical Trial to Evaluate the Efficacy and Safety of Udenafil Dosed Once a Day in Patients With Erectile Dysfunction After Bilateral Nerve-sparing Radical Prostatectomy Unknown status NCT03142542 Phase 4 ZYDENA TAB.75mg(Udenafil 75mg);Placebo Oral Tablet
21 Low Dose, Low Concentration Different Baricity Bupivacaine for Transuretral Prostatectomy. Unknown status NCT01861041 Phase 4 Heavy Bupivacaine;Isobaric Bupivacaine
22 Switch Study: Are There Any Measurable Differences When Switching Patients on Finasteride Therapy to Dutasteride? Unknown status NCT00690950 Phase 4 Dutasteride
23 Bioequivalence Study of Tansulosine 0,4 mg Capsule in Health Subjects -Fed State Unknown status NCT01338623 Phase 4 Tansulosine
24 A Multicenter, Randomized, Double-blind, Clinical Study to Investigate the Efficacy and Safety of Treatment With Tamsulosin 0.2mg Mono and Tamsulosin 0.2mg, Finasteride 5mg Combination Therapy in Patients With LUTS/BPH Unknown status NCT01736033 Phase 4 Tamsulosin;Finasteride;Placebo
25 Open Randomized Clinical Trial to Examine Individual Pain Tolerance in the Use of Two Anesthetic Techniques to Perform Saturation Prostate Biopsy Completed NCT02909049 Phase 4 MIDAZOLAM;MEPIVACAÍNE;FENTANILE;KETAMINE
26 Evaluation of the Effects of Monopolar Transurethral Resection Versus Bipolar Transurethral Resection and Holmium Laser Enucleation of the Prostate on Urinary and Sexual Function; a Prospective Comparative Study. Completed NCT01810068 Phase 4
27 Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication and Adherence in Emergency Ward Completed NCT02246361 Phase 4
28 Chronic Bacterial Prostatitis: Efficacy of Short-lasting Antibiotic Therapy With Prulifloxacin (Unidrox®) in Association With Saw Palmetto Extract, Lactobacillus Sporogens and Arbutin (Lactorepens®) Completed NCT02130713 Phase 4 Third generation fluoroquinolone
29 Brain Imaging-based Strategies for Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain Completed NCT02385266 Phase 4 D-Cycloserine;Placebo (for D-cycloserine)
30 Urinary Nerve Growth Factor as a Biomarker for Medical Treatment of Male Lower Urinary Tract Symptoms: A Pilot Trial Completed NCT01457573 Phase 4 Tamsulosin;Solifenacin
31 Green Light Laser (XPS) Photoselective Vaporization of the Prostate (PVP) Versus Bipolar Transurethral Vaporization (B.TUVP) of the Prostate for Treatment of Small to Moderate Sized Benign Prostate Hyperplasia: A Randomized Study Completed NCT02283684 Phase 4
32 Randomized Study Comparing Holmium Laser Enucleation of the Prostate (HOLEP) Versus Greenlight (XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP) in the Management of Infravesical Obstruction Secondary to BPH Completed NCT01494337 Phase 4
33 A Randomized, Open-label, Parallel-group Study, to Assess the Pharmocodynamic Effect on Dihydrotestosterone Regulated Gene Expression, Longitudinally and in a Dose Dependent Manner, of 0.5mg and 3.5mg Dutasteride Administered Orally Once Daily, for One Year in Men With Symptomatic Benign Prostatic Hyperplasia and During a Two Month Period Between Baseline and Radical Prostatectomy in Men With Biopsy-proven, Clinically Localized Prostate Cancer Completed NCT00375765 Phase 4 Dutasteride
34 An Open-Label Randomized Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia Completed NCT01500057 Phase 4
35 Effectiveness of Testosterone Replacement Therapy (TRT) on Prostatic Gland in Hypogonadal Patients Affected by Benign Prostatic Hyperplasia (BPH) and Metabolic Syndrome (MetS). Florence-PROTEST Completed NCT02366975 Phase 4 Testosterone gel 2%
36 Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer Completed NCT00219271 Phase 4 Zoledronic acid
37 Randomized, Double-Blind, Placebo-Controlled Trial Assessing The Efficacy And Safety Of Dutasteride At Improving Lower Urinary Tract Symptoms In Men With Clinically Localized Prostate Cancer Being Treated With Single-Dose Goserelin, Trans-Urethral Incision Of Prostate, And Interval Brachytherapy Completed NCT00805701 Phase 4 avodart;Placebo
38 Dutasteride in Men Receiving Testosterone Therapy: Impact on Serum PSA, Testosterone, DHT Levels and Prostate Volume: "Implications for Prostate Safety" Completed NCT00752869 Phase 4 dutasteride;placebo
39 Understanding Experimentally Induced Hot Flushes and Their Impact on Sleep and Mood Completed NCT00455689 Phase 4 Leuprolide acetate
40 Benign Prostatic Hyperplasia and Ischemic Heart DIsease Completed NCT03856242 Phase 4 Tamsulosin Oral Capsule
41 Implementation of a Screening Tool for Subjects With Benign Prostatic Enlargement/Obstruction to Identify Men >=50 Years Presenting in General Practice With Other Co-morbidities Who Should be Assessed for BPH Completed NCT02757963 Phase 4
42 A Multi-center, Prospective, Open-label, Single-arm, 12-weeks, Phase IV Trial to Evaluate the Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia Completed NCT02106182 Phase 4 Silodosin
43 Evaluation of Directed Antimicrobial Prophylaxis for Transrectal Ultrasound Guided Prostate Biopsy (TRUSP) Completed NCT01659866 Phase 4 Ciprofloxacin;trimethoprim-sulfamethoxazole;cefuroxime;ceftriaxone;gentamicin;amikacin;aztreonam;imipenem;ceftriaxone;gentamicin;amikacin;aztreonam;imipenem
44 A Prospective Clinical Study for GreenLight HPS in the Treatment of Obstructive Benign Prostatic Hyperplasia (BPH) Completed NCT00465101 Phase 4
45 A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride in Extending the Time to Progression of Low-Risk, Localized Prostate Cancer in Men Who Are Candidates for or Undergoing Expectant Management Completed NCT00363311 Phase 4 Dutasteride;Matching placebo
46 A Prospective Evaluation of the GreenLight Model 120 Laser System for the Treatment of Benign Prostatic Hyperplasia Completed NCT00364585 Phase 4
47 A Prospective, Single-arm Multicenter Study to Evaluate Effect of Intravenous Zoledronic Acid on Bone Metabolism Given Over 4 Months in Patients With Prostate Cancer or Breast Cancer and Bone Metastasis Completed NCT00334139 Phase 4 Zoledronic Acid
48 Phase IV Study of Safety and Efficacy of Docetaxel in Combination With Prednisone in Advanced Hormone Refractory Prostate Cancer Treatment Completed NCT00280098 Phase 4 docetaxel
49 Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases Completed NCT00242554 Phase 4 Zoledronic acid
50 Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis Completed NCT00241111 Phase 4 zoledronic acid

Search NIH Clinical Center for Prostatitis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Ciprofloxacin

Cochrane evidence based reviews: prostatitis

Genetic Tests for Prostatitis

Anatomical Context for Prostatitis

MalaCards organs/tissues related to Prostatitis:

40
Prostate, Bone, Lymph Node, T Cells, Bone Marrow, Colon, Breast

Publications for Prostatitis

Articles related to Prostatitis:

(show top 50) (show all 5897)
# Title Authors PMID Year
1
Association between periodontal disease and prostate-specific antigen levels in chronic prostatitis patients. 54 61
20450358 2010
2
[Clinical analysis of benign prostate hyperplasia with prostatitis]. 61 54
20448364 2010
3
Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach. 61 54
20177031 2010
4
Antibacterial therapy improves the effectiveness of prostate cancer detection using prostate-specific antigen in patients with asymptomatic prostatitis. 54 61
19548108 2010
5
Crucial role of interferon-gamma in experimental autoimmune prostatitis. 54 61
20096883 2010
6
Is it possible to predict sepsis, the most serious complication in prostate biopsy? 61 54
20224265 2010
7
Prostate specific antigen, pelvic pain and prostatitis--time for a new paradigm? 54 61
19524944 2009
8
Aggressiveness of inflammation in histological prostatitis--correlation with total and free prostate specific antigen levels in men with biochemical criteria for prostate biopsy. 61 54
19725275 2009
9
Management of elevated prostate-specific antigen in men with nonbacterial chronic prostatitis. 61 54
19570492 2009
10
An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans. 61 54
19603556 2009
11
Impact of vitamin D receptor activity on experimental autoimmune prostatitis. 54 61
19269787 2009
12
Influence of inflammation and aging on macrophage inhibitory cytokine-1 gene expression in rat ventral prostate. 61 54
18929399 2009
13
Incidence of histological prostatitis and its correlation with PSA density. 54 61
19936177 2009
14
Exclusion of inflammation in the differential diagnosis of an elevated prostate-specific antigen (PSA). 54 61
19111800 2009
15
[Wardenafil in combined treatment of patients with chronic bacterial prostatitis]. 54 61
19256057 2008
16
Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases. 54 61
18668524 2008
17
Control of autoimmune diseases by the vitamin D endocrine system. 54 61
18594491 2008
18
The issue of prostate cancer evaluation in men with elevated prostate-specific antigen and chronic prostatitis. 61 54
18336465 2008
19
Prevalence of delayed clinician response to elevated prostate-specific antigen values. 54 61
18380989 2008
20
Serum PSA and percent free PSA value changes after antibiotic treatment. A diagnostic method in prostate cancer suspects with asymptomatic prostatitis. 54 61
18362491 2008
21
Prostate Cancer Specificity of PCA3 Gene Testing: Examples from Clinical Practice. 61 54
18836536 2008
22
PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients. 61 54
17637759 2008
23
Reduction of PSA values by combination pharmacological therapy in patients with chronic prostatitis: implications for prostate cancer detection. 61 54
17695414 2007
24
Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). 61 54
17241782 2007
25
Serum prostate-specific antigen levels in Middle Eastern men with subclinical prostatitis. 61 54
17159365 2007
26
Mechanism of Phosphodiesterase 5 inhibitor relief of prostatitis symptoms. 61 54
17300876 2007
27
The correlation between serum prostate specific antigen levels and asymptomatic inflammatory prostatitis. 54 61
17111077 2007
28
Stage T2 prostate cancer presented with high serum prostate specific antigen and nonspecific bone lesions. 54 61
18595241 2007
29
Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. 61 54
17142748 2006
30
Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men. 54 61
16890703 2006
31
Clinical significance of urinary white blood cell count and serum C-reactive protein level for detection of non-palpable prostate cancer. 54 61
16882055 2006
32
A sensitive proximity ligation assay for active PSA. 61 54
16800738 2006
33
Dealing with non-cancerous findings on prostate biopsy. 54 61
16630522 2006
34
Age-specific reference ranges for prostate specific antigen-total and free in patients with prostatitis symptoms and patients at risk. 61 54
17318358 2006
35
Effects of chronic bacterial prostatitis on prostate specific antigen levels total and free in patients with benign prostatic hyperplasia and prostate cancer. 61 54
16502048 2006
36
The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis. 54 61
16385194 2006
37
Can the effect of antibiotherapy and anti-inflammatory therapy on serum PSA levels discriminate between benign and malign prostatic pathologies? 54 61
16401916 2006
38
Pharmacological treatment for premature ejaculation. 54 61
16212722 2005
39
Presence of INFgamma-secreting lymphocytes specific to prostate antigens in a group of chronic prostatitis patients. 61 54
15993362 2005
40
Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. 61 54
15947609 2005
41
[Asymptomatic prostatitis: a frequent cause of raising PSA]. 54 61
16209120 2005
42
The vicious cycling: bicycling related urogenital disorders. 61 54
15716187 2005
43
Pure prostatic papillary adenocarcinoma with ductal features. 54 61
15852679 2005
44
Ability of PSA-positive circulating macrophages to detect prostate cancer. 54 61
15389786 2005
45
Effect of NIH-IV prostatitis on free and free-to-total PSA. 61 54
15548444 2004
46
PSA decrease after levofloxacin therapy in patients with histological prostatitis. 54 61
15693428 2004
47
Measurement of intracellular versus extracellular prostate-specific antigen levels in peripheral macrophages: a new approach to noninvasive diagnosis of prostate cancer. 61 54
15636686 2004
48
[Effect of inflammatory chronic pelvic pain syndrome on the levels of prostatic specific antigen]. 54 61
15638019 2004
49
Application of serum PSA to identify acute bacterial prostatitis in patients with fever of unknown origin or symptoms of acute pyelonephritis. 61 54
15264238 2004
50
Prostate carcinoma among men with human immunodeficiency virus infection. 61 54
15241826 2004

Variations for Prostatitis

Expression for Prostatitis

Search GEO for disease gene expression data for Prostatitis.

Pathways for Prostatitis

Pathways related to Prostatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 73)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.1 TNF PTGS2 PROS1 IL6 IL4 IL2
2
Show member pathways
13.9 TNF PTGS2 IL6 IL4 IL2 IL1B
3
Show member pathways
13.76 TNF PTGS2 IL6 IL4 IL2 IL1B
4
Show member pathways
13.62 TNF IL6 IL4 IL2 IL1B IL17A
5
Show member pathways
13.5 TNF IL6 IL4 IL2 IL1B IL17A
6
Show member pathways
13.45 TNF PTGS2 IL6 IL4 IL2 IL1B
7
Show member pathways
13.39 TNF IL6 IL4 IL2 IL1B IL17A
8
Show member pathways
13.27 TNF IL6 IL2 IL1B IL10 CXCL8
9
Show member pathways
13.01 TNF PTGS2 IL6 IL1B CXCL8 CCL3
10 12.94 PTGS2 NKX3-1 KLK3 IL6 IL4 IL2
11
Show member pathways
12.89 TNF IL6 IL4 IL2 IL1B IL17A
12
Show member pathways
12.85 TNF IL6 IL2 IL1B CXCL8
13
Show member pathways
12.78 TNF PTGS2 IL6 IL1B CXCL8
14
Show member pathways
12.72 TNF IL6 IL4 IL2 IL1B IL17A
15
Show member pathways
12.7 TNF IL6 IL2 IL1B IL17A IL10
16
Show member pathways
12.7 TNF IL6 IL4 IL2 IL1B IL17A
17 12.63 TNF PTGS2 IL4 IL2 IL1B IL17A
18
Show member pathways
12.46 TNF IL6 IL2 IL10 CXCL8 CCL3
19
Show member pathways
12.45 IL6 IL4 IL2 IL10
20
Show member pathways
12.45 TNF PTGS2 IL6 IL4 IL2 IL1B
21
Show member pathways
12.45 TNF PTGS2 IL6 IL4 IL1B IL17A
22
Show member pathways
12.41 TNF PTGS2 IL6 IL1B CXCL8
23
Show member pathways
12.37 TNF PTGS2 IL4 IL1B IL10
24
Show member pathways
12.36 TNF IL6 IL4 IL2 IL1B IL17A
25 12.34 VDR TNF IL6 IL1B IL10
26
Show member pathways
12.34 TNF PTGS2 IL6 IL2 IL1B IL10
27 12.3 TNF IL6 IL1B CXCL8
28
Show member pathways
12.3 TNF IL6 IL4 IL1B CXCL8
29 12.3 TNF NKX3-1 IL6 IL1B IL10 CXCL8
30 12.21 TNF IL6 IL2 IL1B IL10 CXCL8
31 12.12 TNF IL6 IL4 IL2 IL10
32
Show member pathways
12.08 IL4 IL2 IL1B CCL3
33 12.07 TNF PTGS2 IL6 IL1B
34 12.06 TNF IL6 IL1B IL10 CXCL8
35 12.04 IL6 IL1B CXCL8 CCL3
36 12.03 TNF PTGS2 IL1B CXCL8
37 12.01 TNF IL6 IL1B CXCL8
38 12 TNF IL6 IL4 IL1B
39
Show member pathways
11.97 IL6 IL17A FOXP3 CXCL8
40 11.97 TNF IL6 IL1B IL17A CXCL8 CCL3
41
Show member pathways
11.96 IL6 IL4 IL1B IL17A
42 11.94 TNF PTGS2 IL6 IL4 IL2 IL1B
43 11.92 IL6 IL4 IL2 CXCL8
44 11.91 TNF IL6 IL1B IL10 CXCL8
45 11.88 TNF IL6 IL2 IL1B IL10
46 11.82 TNF IL6 IL4 IL10 FOXP3
47
Show member pathways
11.81 TNF IL6 IL2 IL1B IL17A IL10
48
Show member pathways
11.79 TNF PTGS2 IL4 IL2 FOXP3 CXCL8
49
Show member pathways
11.75 IL4 IL2 FOXP3
50 11.74 TNF IL6 IL1B CXCL8

GO Terms for Prostatitis

Cellular components related to Prostatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 TNF PROS1 MSMB KLK3 IL6 IL4
2 extracellular space GO:0005615 9.44 TNF PROS1 MSMB KLK3 IL6 IL4

Biological processes related to Prostatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 10.16 TNF NKX3-1 IL6 IL4 IL1B IL10
2 positive regulation of cell proliferation GO:0008284 10.15 PTGS2 NKX3-1 IL6 IL4 IL2 IL1B
3 positive regulation of transcription by RNA polymerase II GO:0045944 10.15 VDR TNF NKX3-1 IL6 IL4 IL2
4 cell-cell signaling GO:0007267 10.02 IL2 IL1B IL17A CCL3 ADRA1A
5 positive regulation of protein phosphorylation GO:0001934 10.01 TNF NKX3-1 IL2 IL1B
6 response to lipopolysaccharide GO:0032496 10 PTGS2 IL1B IL10 FOXP3
7 negative regulation of gene expression GO:0010629 10 VDR TNF NKX3-1 FOXP3 CXCL8 CCL3
8 negative regulation of inflammatory response GO:0050728 9.98 IL4 IL2 IL10 FOXP3
9 cellular response to lipopolysaccharide GO:0071222 9.95 TNF IL6 IL1B IL10 CXCL8
10 positive regulation of inflammatory response GO:0050729 9.93 TNF IL2 IL1B CCL3
11 positive regulation of interleukin-6 production GO:0032755 9.91 TNF IL6 IL1B IL17A
12 inflammatory response GO:0006954 9.91 TNF PTGS2 IL6 IL1B IL17A CXCL8
13 positive regulation of gene expression GO:0010628 9.91 VDR TNF NKX3-1 IL6 IL4 IL1B
14 negative regulation of tumor necrosis factor production GO:0032720 9.9 IL4 IL10 FOXP3
15 regulation of insulin secretion GO:0050796 9.9 TNF IL6 IL1B
16 negative regulation of interleukin-6 production GO:0032715 9.9 TNF IL10 FOXP3
17 cellular response to interleukin-1 GO:0071347 9.9 NKX3-1 IL17A